Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder 

See more here


Immunome Appoints Dr. Dennis Giesing as Chief Development Officer

– Pharmaceutical industry veteran brings more than three decades of experience developing innovative therapies –

See more here


Ride Health to Provide Non-Emergency Transportation for Complex Patient Populations Across New York State Through Partnership With IMSNY

See more here


Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing

IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies

Raised $44.9 million in gross proceeds in NASDAQ IPO 

Program updates expected in 2Q 2021

See more here


Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp. 

– Renovacor, Inc. has entered into a de􀁾nitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) – 
– Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol “RCOR” – 
– The business combination is expected to be completed in the second quarter of 2021 – 

See more here


Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies

First oncology product candidate identified using the company’s human memory B-cell platform, and intended for potential treatment of solid tumors  

See more here


ArchCare Delivers PACE Participants Seamless, Free Transportation

Technology-Based Ride System Will Serve 702 Home-Based Elderly  

See more here


Annovis Bio Announces Positive Phase 2 Data – Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson’s Patients

See more here


Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late-Stage Studies

See more here


Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate 

VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021  

See more here